Orforglipron (Foundayo) and the Wegovy pill (oral semaglutide 25 mg) are both FDA-approved once-daily GLP-1 pills for weight management: Foundayo on April 1, 2026, the Wegovy pill on December 22, 2025. Both rest on Human RCT evidence. In separate placebo-controlled trials (a cross-trial comparison), the Wegovy pill’s average weight loss was larger (13.6% at week 64) than orforglipron’s top dose (11.2% at week 72). Orforglipron has the larger trial program and no food or water rules.
No trial has compared the two pills directly in people with obesity (ClinicalTrials.gov, searched 2026-10-06). The only head-to-head study, ACHIEVE-3, was run in type 2 diabetes against the lower semaglutide doses sold as Rybelsus, not the 25 mg Wegovy pill.
| Item | Orforglipron (Foundayo) | Wegovy pill (oral semaglutide 25 mg) |
|---|---|---|
| US FDA status | Approved 2026-04-01 for chronic weight management in adults (NDA 220934) | Approved 2025-12-22 for weight management and cardiovascular risk reduction in adults (NDA 218316) |
| Compounding (503A/503B) | No FDA compounding statement on orforglipron found (FDA GLP-1 pages checked 2026-10-06) | Semaglutide off the shortage list; FDA proposed 503B bulks exclusion 2026-04-30; comments closed 2026-06-29; no final action found on FDA’s site (checked 2026-10-06) |
| WADA 2026 | Not named on the 2026 Prohibited List; GLP-1 agonists unchanged for 2027 | Not prohibited; semaglutide markers on the 2026 Monitoring Program |
| Strongest evidence | Approved label; Human RCT (ATTAIN-1, n=3,127) | Approved label; Human RCT (OASIS 4, n=307) |
| Human trials | 27 phase 3 records on ClinicalTrials.gov (e.g. NCT05869903) | Pivotal 25 mg obesity trial NCT05564117; label also draws on semaglutide injection trials |
| Next regulatory step | Lilly has submitted it for type 2 diabetes in the US, EU and Japan; no decision date announced | None announced in the US; tablets now part of the EU Wegovy authorisation |
| Last checked | 2026-10-06 | 2026-10-06 |
Key points:
- Orforglipron is a small, non-peptide molecule; the Wegovy pill is the semaglutide peptide plus an absorption enhancer, and only about 1% to 2% of each dose reaches the blood, according to the Wegovy label.
- The Wegovy pill must be taken on an empty stomach with a 30-minute wait; the Foundayo label allows it with or without food.
- Only the Wegovy pill carries a cardiovascular risk-reduction indication; orforglipron’s placebo-controlled outcomes trial is recruiting, with primary completion estimated for 2031.
- A Novo Nordisk-funded indirect comparison favored the Wegovy pill on weight loss and on stopping for side effects; it is not a head-to-head trial.
- Neither drug is prohibited by WADA, and WADA says GLP-1 status stays unchanged for 2027.
Orforglipron vs Wegovy pill at a glance
| Feature | Orforglipron (Foundayo) | Wegovy pill |
|---|---|---|
| What it is | Once-daily tablet, Eli Lilly | Once-daily tablet, Novo Nordisk |
| Class | Small-molecule, non-peptide GLP-1 receptor agonist | Peptide GLP-1 receptor agonist (semaglutide) with SNAC absorption enhancer |
| Receptor | GLP-1 receptor (label) | GLP-1 receptor (label) |
| Main research focus | Obesity, type 2 diabetes, weight maintenance, cardiovascular safety | Obesity; cardiovascular claim bridged from semaglutide injection data |
| Key human trials | ATTAIN-1, ATTAIN-2, ATTAIN-MAINTAIN | OASIS 4 (25 mg); OASIS 1 tested 50 mg |
| Approval status (US) | Approved 2026-04-01 | Approved 2025-12-22 |
| WADA | Not on the 2026 List | Not on the 2026 List; monitored |
| Food rules | With or without food | Empty stomach, up to 4 oz water, 30-minute wait |
| Half-life | About 29 to 49 hours | About 1 week |
| Label drug interactions | Mainly CYP3A4-metabolized; strong inhibitors and inducers change levels | Raised total levothyroxine exposure by 33% |
| Primary trial timepoint | Week 72 | Week 64 |
| Main safety concerns | GI effects, pancreatitis, gallbladder disease, pulse rise, boxed thyroid warning | GI effects, pancreatitis, gallbladder disease, dysesthesia, boxed thyroid warning |
What is orforglipron (Foundayo)?
Orforglipron is an oral, small-molecule GLP-1 receptor agonist from Eli Lilly, licensed from Chugai, according to Lilly’s quarterly SEC filing. Unlike semaglutide, it is not a peptide. The Foundayo label reports 77% absolute bioavailability after a 0.8 mg dose and no clinically relevant food effect (Approved label). FDA approved it on April 1, 2026, 50 days after filing, the fastest new-molecular-entity approval since 2002, under the Commissioner’s National Priority Voucher pilot program. Its indication is weight reduction and long-term maintenance in adults with obesity, or overweight plus at least one weight-related condition.
What is the Wegovy pill?
The Wegovy pill is semaglutide, the same peptide as Wegovy injection, in a 25 mg once-daily tablet co-formulated with salcaprozate sodium (SNAC), which helps semaglutide be absorbed, mainly in the stomach. The Wegovy label lists two adult indications for the tablets: weight reduction and maintenance, and reducing the risk of cardiovascular death, heart attack or stroke in adults with established cardiovascular disease and obesity or overweight (Approved label). Novo Nordisk states the approval was based on the OASIS program and the SELECT trial, supported by STEP and PIONEER PLUS data. SELECT tested the injection, not the pill.
How they work differently
- Orforglipron: a non-peptide molecule that binds and activates the human GLP-1 receptor (Approved label); FDA’s acting drug-center director called it a “GLP-1 receptor partial agonist pill”.
Wegovy pill: a peptide GLP-1 receptor agonist with a half-life of about one week (Approved label). - Orforglipron: the label gives a half-life of about 29 to 49 hours and metabolism mainly through the liver enzyme CYP3A4, so some drugs that block or speed up CYP3A4 change its levels.
Wegovy pill: absorbed mainly in the stomach with SNAC; the label gives about 1% to 2% bioavailability and requires a 30-minute wait before food, drinks or other oral medicines. - Orforglipron: not pharmacologically active in rats or mice and produced no thyroid tumors in rodents, yet still carries the class boxed warning because human relevance is undetermined.
Wegovy pill: semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures; same boxed warning.
Evidence head-to-head: orforglipron vs Wegovy pill for weight loss
Each drug has strong placebo-controlled data; the trials differ in length, size and population, so every comparison below is cross-trial unless stated. In ATTAIN-1 (Human RCT, n=3,127, adults without diabetes), the 36 mg arm lost 11.2% of body weight at week 72 versus 2.1% with placebo, and 18.4% of that arm lost 20% or more. In OASIS 4 (Human RCT, n=307, adults without diabetes), the Wegovy pill group lost 13.6% at week 64 versus 2.2% with placebo. Both are intention-to-treat estimates that include people who stopped the drug; the labels show 11.1% for orforglipron’s equivalent 17.2 mg tablet and 13.6% for the Wegovy pill. The 16.6% figure in Novo Nordisk’s release is a different estimate: what happens “if all people adhered to treatment”.
A population-adjusted indirect comparison of these two trials, written by Novo Nordisk employees and funded by Novo Nordisk, estimated 3.2 percentage points more weight loss with the Wegovy pill (95% CI 0.4 to 5.9) and higher odds of stopping for side effects with orforglipron (odds ratio 4.1). The wide confidence intervals and sponsor funding limit how far this can be read.
In type 2 diabetes, the only direct comparison favors orforglipron on blood sugar. ACHIEVE-3 (Human RCT, open-label, n=1,698) found orforglipron 36 mg lowered HbA1c by 1.91% versus 1.47% with oral semaglutide 14 mg over 52 weeks, a significant difference of 0.44% (p<0.0001). It also had more gastrointestinal events (58% vs 45%) and more stops for side effects (10% vs 5%).
| Outcome | Orforglipron best evidence | Wegovy pill best evidence |
|---|---|---|
| Weight loss, no diabetes | Human RCT, n=3,127: −11.2% vs −2.1% at 72 wk (ATTAIN-1) | Human RCT, n=307: −13.6% vs −2.2% at 64 wk (OASIS 4) |
| Weight loss with type 2 diabetes | Human RCT, n=1,613: −9.6% vs −2.5% at 72 wk (ATTAIN-2) | No 25 mg weight trial in diabetes on the label; OASIS 4 excluded diabetes |
| Blood sugar (HbA1c) | Human RCT, n=1,698: superior to oral semaglutide 7 and 14 mg (ACHIEVE-3) | Same trial, as comparator at lower doses |
| Keeping weight off after injections | Human RCT, n=376: kept 79.3% of prior loss vs 37.6% on placebo after semaglutide (ATTAIN-MAINTAIN) | No maintenance trial found on ClinicalTrials.gov (2026-10-06) |
| Heart attack, stroke, CV death | Human RCT, n=2,749: non-inferior to insulin glargine, HR 0.84 (ACHIEVE-4) | Approved label: risk reduction, based on injection trial SELECT, HR 0.80 (label) |
| Liver safety | Pooled 7 phase 3 trials, n=11,220: no Hy’s Law cases (pooled analysis) | No pooled liver analysis found in the sources reviewed |
How do the pills compare with Wegovy injections?
The Wegovy label reports that, in people without type 2 diabetes, average semaglutide blood levels with the 25 mg tablet and the 2.4 mg weekly injection “were similar” (Approved label). In the injection’s STEP 1 trial, shown on the same label, people lost 14.9% at week 68 versus 2.4% with placebo (Human RCT, n=1,961). A Novo Nordisk-funded indirect comparison of OASIS 4 and STEP 1 found a 1.01-point numerical edge for the injection, with a confidence interval crossing zero, and called the two “comparable”. For readers weighing pills against newer injectables, our retatrutide vs tirzepatide vs semaglutide comparison and CagriSema vs Zepbound comparison cover those trials.
Which fits which goal?
- Average weight loss in people without diabetes: the Wegovy pill has the larger single-trial result (13.6% vs 11.2%, cross-trial), from a smaller trial of 307 people.
- Weight loss with type 2 diabetes and blood-sugar control: orforglipron has more evidence, including the ATTAIN-2 obesity-with-diabetes trial and a head-to-head HbA1c win over oral semaglutide at Rybelsus doses.
- Cardiovascular risk reduction: only the Wegovy pill has an approved indication, carried over from semaglutide injection data; orforglipron has a safety result versus insulin glargine and a placebo-controlled outcomes trial still running.
- Staying on weight loss after an injection: orforglipron has a randomized switch trial, ATTAIN-MAINTAIN, though it had no arm that stayed on injections; no such trial was found for the Wegovy pill (ClinicalTrials.gov, searched 2026-10-06).
- Daily routine: orforglipron has no food or water rules; the Wegovy pill has a fasting routine set by its label.
These are statements about evidence, not a recommendation. A clinician who knows a person’s history, other medicines and goals is the person to decide.
Can they be combined?
No. Both labels say use with another GLP-1 receptor agonist is not recommended: the Foundayo label and the Wegovy label both state it under limitations of use. No controlled human study has tested the combination (ClinicalTrials.gov, searched 2026-10-06). The closest data are sequential: ATTAIN-MAINTAIN moved people from injectable semaglutide or tirzepatide onto orforglipron, one drug at a time.
Orforglipron vs Wegovy pill side effects, safety and regulatory status
Side effects. Both drugs mostly cause gastrointestinal effects. In the Foundayo label’s pooled trials, gastrointestinal reactions hit 69% at the top dose versus 37% on placebo, nausea 35% versus 10%, vomiting 24% versus 4%, and 8% stopped for side effects versus 3%. Hair loss was reported in 5% versus 2%, and pulse rose by 4.6 beats per minute at the top dose in Trial 1 versus 0.6 on placebo (Approved label). For the tablet, the Wegovy label reports 6.9% stopping for side effects versus 5.9%, severe gastrointestinal reactions in 2% versus 0%, dysesthesia (altered skin sensation) in 5% versus 0, and gallstones in 2.5% versus 1% (Approved label). In OASIS 4, gastrointestinal events affected 74.0% versus 42.2% on placebo.
Shared warnings. Both carry a boxed warning for thyroid C-cell tumors and must not be used with a personal or family history of medullary thyroid cancer or MEN 2. FDA’s approval notice lists pancreatitis, acute kidney injury, gallbladder disease, low blood sugar with other diabetes drugs, and aspiration under anesthesia among Foundayo’s warnings. A Lilly-authored pooled analysis of 6,920 orforglipron-treated people found no case meeting Hy’s Law for drug-induced liver injury.
United States. Both are prescription drugs approved by FDA. FDA says unapproved GLP-1 versions “do not undergo FDA’s review for safety, effectiveness and quality” and has seen fraudulent compounded semaglutide. Semaglutide is no longer on FDA’s shortage list, which limits copies by compounders, and FDA proposed excluding it from the 503B bulks list. No FDA compounding statement names orforglipron (checked 2026-10-06), and openFDA’s shortage database has no orforglipron entry. For broader context on unapproved products, see what the evidence and the FDA say about peptide safety.
European Union. The EMA’s Wegovy page lists tablets for adults alongside the pens. Orforglipron had no entry in EMA’s medicines database (checked 2026-10-06); Lilly’s quarterly filing reports submissions in all major markets.
Sport. WADA’s 2026 List names no GLP-1 receptor agonist. Its S0 class bans only substances with no current approval by any government health authority, and orforglipron is FDA-approved. WADA monitors semaglutide and tirzepatide markers, and its 2027 List announcement said there is “not enough evidence” yet to add GLP-1 drugs while one sport-related study runs and a second begins.
How long do effects take in studies?
Both drugs start at a low dose and are stepped up over months to reduce gastrointestinal side effects. In OASIS 4 the tablet reached 25 mg over a 12-week escalation, followed by 52 weeks of maintenance, and the primary result was read at week 64 (Wegovy label). Orforglipron’s primary results were read at week 72; the Foundayo label notes steady blood levels after about one week on a given dose and that nausea, vomiting and diarrhea were most common during escalation and decreased over time.
What users report
This section summarizes unverified self-reports posted online, some by people using products bought outside regulated pharmacies; it is not evidence. People who post about the Wegovy pill commonly describe appetite suppression within the first weeks and talk at length about the morning routine of an empty stomach and the 30-minute wait, which some find hard to keep. People posting about Foundayo often say the lack of food rules is the main reason they chose it, and a recurring complaint is nausea or vomiting after a dose increase. Across both, frequent topics are constipation, fatigue, insurance coverage and whether a pill feels as strong as an injection. People switching from injections argue about whether weight loss stalls or continues on a pill. Some report hair shedding and a faster heartbeat, and some say they stopped because of stomach side effects. These posts cannot show how common any effect is.
Frequently asked questions
Is orforglipron better than the Wegovy pill for weight loss?
There is no head-to-head obesity trial. In separate trials, the Wegovy pill’s group lost 13.6% at 64 weeks and orforglipron’s top dose 11.2% at 72 weeks, and a Novo Nordisk-funded indirect comparison favored the Wegovy pill. Different trial designs mean these numbers suggest, rather than prove, a difference.
Is Foundayo the same as orforglipron?
Yes. Foundayo is Eli Lilly’s brand name for orforglipron tablets. FDA approved it on April 1, 2026, under NDA 220934, for adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. Lilly has also submitted it for type 2 diabetes.
Do orforglipron and the Wegovy pill have the same side effects?
Largely, yes: both mainly cause nausea, vomiting, diarrhea and constipation, and both carry a thyroid tumor boxed warning. In the one direct comparison, ACHIEVE-3 in type 2 diabetes, orforglipron caused more gastrointestinal events, more treatment stops and a larger pulse rise than oral semaglutide at lower doses.
Can you switch from Wegovy injections to a pill?
The Wegovy label describes switching between the 2.4 mg injection and the 25 mg tablet, a decision for the prescriber. For orforglipron, ATTAIN-MAINTAIN found people coming off semaglutide injections who had reached a weight plateau kept an estimated 79.3% of their earlier weight loss after 52 weeks on orforglipron, versus 37.6% on placebo.
Are GLP-1 pills banned for athletes?
No. Neither orforglipron nor semaglutide appears on the WADA 2026 Prohibited List, and WADA kept GLP-1 drugs unchanged for 2027 pending more data. Semaglutide and tirzepatide markers are tracked in WADA’s Monitoring Program, so athletes should still confirm with their anti-doping organization.
References
- US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program (Foundayo). Press release, 2026-04-01. fda.gov
- US Food and Drug Administration. Drugs@FDA: NDA 220934, Foundayo (orforglipron). accessdata.fda.gov
- Eli Lilly and Company. Foundayo (orforglipron) tablets, prescribing information. DailyMed, 2026. dailymed.nlm.nih.gov
- US Food and Drug Administration. Drugs@FDA: NDA 218316, Wegovy (semaglutide) tablets. accessdata.fda.gov
- Novo Nordisk. Wegovy (semaglutide) injection and tablets, prescribing information. DailyMed, 2026. dailymed.nlm.nih.gov
- Novo Nordisk A/S. Form 6-K: Wegovy pill approved in the US as first oral GLP-1 for weight management. SEC, 2025-12-22. sec.gov
- Eli Lilly and Company. Form 10-Q for the quarter ended June 30, 2026. SEC. sec.gov
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796-1806. PubMed
- Horn DB, Ryan DH, Kis SG, et al. Orforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). Lancet. 2026;406(10522):2927-2944. PubMed
- Rosenstock J, Yabe D, Cox D, et al. Once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. 2026;407(10534):1147-1160. PubMed
- Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087. PubMed
- Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402(10403):705-719. PubMed
- Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN). Nat Med. 2026;32(7):2679-2687. PubMed
- Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes (ACHIEVE-4). Lancet. 2026 (online ahead of print). PubMed
- Wharton S, Stefanski A, Chen J, et al. Hepatic Safety of Orforglipron: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials. Diabetes Obes Metab. 2026;28(9):8347-8358. PubMed
- Michalak W, Bøg M, Bendixen T, et al. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. Diabetes Obes Metab. 2026;28(8):7247-7256. PubMed
- Plotkin M, Ivkovic M, Smith I, et al. Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison. Diabetes Obes Metab. 2026;28(8):7237-7246. PubMed
- ClinicalTrials.gov. NCT05869903 (ATTAIN-1). clinicaltrials.gov
- ClinicalTrials.gov. NCT05564117 (OASIS 4). clinicaltrials.gov
- ClinicalTrials.gov. NCT07241390, orforglipron cardiovascular outcomes trial. clinicaltrials.gov
- European Medicines Agency. Wegovy: EPAR medicine overview. ema.europa.eu
- World Anti-Doping Agency. 2026 Prohibited List. wada-ama.org
- World Anti-Doping Agency. 2026 Monitoring Program. wada-ama.org
- World Anti-Doping Agency. WADA publishes 2027 Prohibited List. 2026-09-21. wada-ama.org
- US Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. 2026-04-30. fda.gov
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. fda.gov
- US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. fda.gov
Change log
2026-10-19: links to related entries added; no change to the facts.
2026-10-13: first published after review by the editorial team.